Forte Biosciences (FBRX) Projected to Post Earnings on Friday

Forte Biosciences (NASDAQ:FBRX) is projected to release its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect Forte Biosciences to post earnings of ($1.42) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Forte Biosciences Price Performance

Shares of FBRX opened at $25.72 on Wednesday. The stock has a market capitalization of $322.27 million, a price-to-earnings ratio of -7.75 and a beta of 3.24. Forte Biosciences has a 1 year low of $4.90 and a 1 year high of $35.62. The business’s 50 day simple moving average is $29.71 and its 200-day simple moving average is $21.88.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Evercore initiated coverage on shares of Forte Biosciences in a research report on Tuesday, November 25th. They issued an “outperform” rating and a $65.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Forte Biosciences in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Institutional Trading of Forte Biosciences

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in Forte Biosciences by 6.7% during the second quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock worth $829,000 after buying an additional 4,028 shares during the period. Orbimed Advisors LLC lifted its holdings in shares of Forte Biosciences by 101.8% in the 2nd quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock worth $15,477,000 after acquiring an additional 603,867 shares during the last quarter. Cable Car Capital LP boosted its stake in shares of Forte Biosciences by 127.7% during the 2nd quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock worth $6,465,000 after purchasing an additional 280,396 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in Forte Biosciences during the 2nd quarter valued at about $4,310,000. Finally, Mink Brook Asset Management LLC purchased a new stake in Forte Biosciences in the 2nd quarter worth about $503,000. 77.63% of the stock is currently owned by institutional investors.

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.